¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦11Â÷ International Congress on Lipid & Atherosclerosis (ICoLA 2022) 3ÀÏÂ÷ : 2022-09-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦11Â÷ International Congress on Lipid & Atherosclerosis (ICoLA 2022) 3ÀÏÂ÷ : 2022-09-17
±³À°ÀÏÀÚ : 2022-09-17
±³À°Àå¼Ò : ¿©Àǵµ ÄÜ·¡µå È£ÅÚ  
±³À°ÁÖÁ¦ : Á¦11Â÷ International Congress on Lipid & Atherosclerosis (ICoLA 2022) 3ÀÏÂ÷
ÁÖÃÖ±â°ü : Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ
´ã´çÀÚ : ICoLA2022 »ç¹«±¹
¿¬¶ôó : 02-2285-2507  
À̸ÞÀÏ : secretariat@icola2022.org      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 18 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 140,000¿ø      
ºñ°í Àü¹®ÀÇ, ±³¼ö : »çÀüµî·Ï 120,000¿ø, ÇöÀåµî·Ï 140,000¿ø / ÀüÀÓÀÇ, Àü°øÀÇ,Çлý µî : »çÀüµî·Ï 60,000¿ø, ÇöÀåµî·Ï 70,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-17 Room 1 08:00~08:30 Lipid management : To the perfection and state of art  HyoIn Choi(Sunkyunkwan University, Korea) 
Åä·Ð 09-17 Room 1 08:30~08:40 Discussion  () 
±³À°½Ã°£ 09-17 Room 2 08:00~08:30 Management of Poorly Controlled Patients with Diabetes Mellitus  Yong-ho Lee(Yonsei University, Korea) 
Åä·Ð 09-17 Room 2 08:30~08:40 Discussion  () 
±³À°½Ã°£ 09-17 Room 1,2,3 09:00~09:40 New look at PCSK9 metabolism & its clinical implications  Sergio Fazio(Stanford University, USA) 
È޽Ġ09-17  09:40~09:45 Break  () 
±³À°½Ã°£ 09-17 Room 1 09:45~10:05 What is currently best & changing in treatment of adults with Familial Hypercholesterolaemia (FH)?  Won Jae Lee(Seoul National University, Korea) 
±³À°½Ã°£ 09-17 Room 1 10:05~10:25 Update on familial vs mulitifactorial chylomicronemia syndrome  Heung Yong Jin(Jeonbuk National University, Korea) 
±³À°½Ã°£ 09-17 Room 1 10:25~10:45 Understanding role of ANGPTL3 & neighbor molecules  Hun-Jun Park(The Catholic University of Korea, Korea) 
Åä·Ð 09-17 Room 1 10:45~11:10 Discussion  () 
±³À°½Ã°£ 09-17 Room 2 09:45~10:05 Impact of lipases on human dyslipidemia & atherosclerosis  Hayato Tada(Kanazawa University, Japan) 
±³À°½Ã°£ 09-17 Room 2 10:05~10:25 Screening new genes for therapeutics against dyslipidemia & atherosclerosis  Alan Remaley(National Institute of Health, USA) 
±³À°½Ã°£ 09-17 Room 2 10:25~10:45 Understanding strength & limitation of platforms in drug development  Dong Ki Lee(OliX Pharmaceuticals, Korea) 
Åä·Ð 09-17 Room 2 10:45~11:10 Discussion  () 
±³À°½Ã°£ 09-17 Room 3 09:45~10:05 Challenges & perspective of drugs for Lp(a)  Gisette Reyes-Soffer(Columbia University, USA) 
±³À°½Ã°£ 09-17 Room 3 10:05~10:25 For whom & how much will bempedoic acid work?  Raul Santos(University of São Paulo, Brazil) 
±³À°½Ã°£ 09-17 Room 3 10:25~10:45 Recent trial results of new drugs targeting TG rich lipoprotein  Eun Ho Choo(The Catholic University of Korea, Korea) 
Åä·Ð 09-17 Room 3 10:45~11:10 Discussion  () 
±³À°½Ã°£ 09-17 Room 4 09:45~10:05 Organ crosstalk under atherogenic diet  Chosoon Jang(University of California Irvine, USA) 
±³À°½Ã°£ 09-17 Room 4 10:05~10:25 Emerging role of epigenetic regulation by nutrients in inflammation & atherosclerosis  Hyun Ju Kang(Keimyung University, Korea) 
±³À°½Ã°£ 09-17 Room 4 10:25~10:45 Transition to metabolically unhealthy status & cardiometabolic risks  Yongjoo Park(Chonnam National University, Korea) 
Åä·Ð 09-17 Room 4 10:45~11:10 Discussion  () 
È޽Ġ09-17  11:15~11:25 Coffee Break  () 
±³À°½Ã°£ 09-17 Room 1,2,3 11:25~12:05 Best approach to cardio & cerebrovascular health in elderly  Hidenori Arai(National Center for Geriatrics & Gerontology, Japan) 
±³À°½Ã°£ 09-17 Room 1 12:05~12:35 Treatment of Dyslipidemia with Rosuvastatin and Ezetimibe  Sang-Hyun Kim(Seoul National University, Korea) 
Åä·Ð 09-17 Room 1 12:35~12:45 Discussion  () 
±³À°½Ã°£ 09-17 Room 2 12:05~12:35 Why should we consider Rosuvastatin + Ezetimibe Fixed Dose Combination  Seung-Woon Rha(Korea University, Korea) 
Åä·Ð 09-17 Room 2 12:35~12:45 Discussion  () 
±³À°½Ã°£ 09-17 Room 3 12:05~12:35 Key Updates in the Recent Guidelines – Identifying Patients for Evolocumab Therapy  WonJae Lee(Seoul National University, Korea) 
Åä·Ð 09-17 Room 3 12:35~12:45 Discussion  () 
±³À°½Ã°£ 09-17 Room 4 12:05~12:35 The time for intensive LLT in very high-risk patients based on the updated Korean guideline  Ho-Youn Won(Chung-Ang University, Korea) 
Åä·Ð 09-17 Room 4 12:35~12:45 Discussion  () 
È޽Ġ09-17  12:55~13:00 Break  () 
±³À°½Ã°£ 09-17 Room 1,2,3 13:00~13:30 Up close & personal with vascular diseases: The role of precision medicine  Maria Teresa Abola(University of the Philippines, Philippines) 
È޽Ġ09-17  13:30~13:35 Break  () 
±³À°½Ã°£ 09-17 Room 1 13:35~13:42 Evaluation of the paradoxical association between lipid levels and incident atrial fibrillation according to statin usage: a nationwide cohort study   Hyojeong Ahn(Seoul National University, Korea) 
±³À°½Ã°£ 09-17 Room 1 13:42~13:49 Comparison of cerebro-cardiovascular prognosis between cholesterol exposure estimate and cholesterol variability   Hyung Joon Joo(Korea University, Korea) 
±³À°½Ã°£ 09-17 Room 1 13:49~13:56 Early change in glucose level and risk of new-on diabetes in patients initiating statin treatment  Choongki Kim(Ewha Womans University, Korea) 
±³À°½Ã°£ 09-17 Room 1 13:56~14:03 Low-density lipoprotein cholesterol level, statin use and myocardial infarction risk in young adults  Mee Kyoung Kim(The Catholic University of Korea, Korea) 
Åä·Ð 09-17 Room 1 14:03~14:20 Q&A  () 
±³À°½Ã°£ 09-17 Room 2 13:35~13:42 Ginsenoside Rh1 abolishes ROS-dependent KLF4 signaling pathway to inhibit proliferation and migration of vascular smooth muscle cells  Diem Thi Ngoc Huynh(Chungnam National University, Korea) 
±³À°½Ã°£ 09-17 Room 2 13:42~13:49 PCSK9 inhibitors inhibit monocyte adherence to stimulated human coronary artery endothelial cells   Rahayu Zulkapli(Universiti Teknologi MARA, Malaysia) 
±³À°½Ã°£ 09-17 Room 2 13:49~13:56 Lipoprotein(a) and cardiovascular and all-cause mortality in Korean adults   Byung Jin Kim(Sungkyunkwan University, Korea) 
±³À°½Ã°£ 09-17 Room 2 13:56~14:03 Saffron: a potential natural alternative remedy for statin intolerance  Iman Nabilah Abd Rahim(Universiti Teknologi MARA, Malaysia) 
Åä·Ð 09-17 Room 2 14:03~14:20 Q&A  () 
È޽Ġ09-17  14:35~14:45 Coffee Break  () 
±³À°½Ã°£ 09-17 Room 1 14:45~15:05 Tips for performing nationwide big cohort studies  Pil-Sung Yang(Cha University, Korea) 
±³À°½Ã°£ 09-17 Room 1 15:05~15:25 Advance of AI utility in past 5 years in ASCVD care: overview  Jun Hwan Cho(Chung-Ang University, Kore) 
±³À°½Ã°£ 09-17 Room 1 15:25~15:45 Device-based care for CV risk factors  Hak Seung Lee(Medical AI, Korea) 
Åä·Ð 09-17 Room 1 15:45~16:10 Discussion  () 
±³À°½Ã°£ 09-17 Room 2 14:45~15:05 What's new in vascular calcification in atherosclerosis?  In-Kyu Lee(Kyungpook National University, Korea) 
±³À°½Ã°£ 09-17 Room 2 15:05~15:25 Celluar senescence in atherosclerosis  Jae-Ryong Kim(Yeungnam University, Korea) 
±³À°½Ã°£ 09-17 Room 2 15:25~15:45 Extracellular vesicles & endothelial cells  Kihwan Kwon(Ewha Womans University, Korea) 
Åä·Ð 09-17 Room 2 15:45~16:10 Discussion  () 
±³À°½Ã°£ 09-17 Room 3 14:45~15:05 Characteristics of dyslipidemia & ASCVD of women in Korea  Mi-Na Kim(Korea University, Korea) 
±³À°½Ã°£ 09-17 Room 3 15:05~15:25 Sex difference in diagnosis & treatment of ASCVD: what do we need to improve in women?  Ping-Yen Liu(National Cheng Kung University, Taiwan) 
±³À°½Ã°£ 09-17 Room 3 15:25~15:45 Is there difference of response to lipid-lowering therapy in women?  Chih-Fan Yeh(National Taiwan University, Taiwan) 
Åä·Ð 09-17 Room 3 15:45~16:10 Discussion  () 
±³À°½Ã°£ 09-17 Room 4 14:45~15:05 Practical approach of PCSK9 Ab use in primary & secondary prevention  Young Joon Hong(Chonnam National University, Korea) 
±³À°½Ã°£ 09-17 Room 4 15:05~15:25 Comparison of two drug platforms (Abs & siRNA)  Richard O¡¯Brien(University of Melbourne, Australia) 
±³À°½Ã°£ 09-17 Room 4 15:25~15:45 Patients who are resistant to or hypo-respond to PCSK9 inhibitors – a therapeutic challenge  Edward Janus(University of Melbourne, Australia) 
Åä·Ð 09-17 Room 4 15:45~16:10 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦11Â÷ International Congress on Lipid & Atherosclerosis (ICoLA 2022) 3ÀÏÂ÷ : 2022-09-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦ 114Â÷ ´ëÇÑÇǺΰúÇÐȸ ÀüºÏÁöºÎȸ : 2022-09-17
´ÙÀ½±Û 2022³â ´ëÇѹ̼¼¼ö¼úÇÐȸ Microsurgery Workshop : 2022-09-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21105 ¼­¿ï Á¦34Â÷ ÀÏÂ÷ÀÇ·áÀÎÀ» À§ÇÑ ³»½Ã°æ ¿¬¼ö°­Á : 2024-07-07 0 11 2024-06-19
21104 ºÎ»ê Á¦6±â ºÎ»ê±¤¿ª½ÃÀÇ»çȸ ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤ : 2024-07-07 0 14 2024-06-19
21103 ´ë±¸ ´ë±¸°æºÏ³»°úÀÇ»çȸ ÇÏ°èÇмú´ëȸ : 2024-07-07 0 11 2024-06-19
21102 ¼­¿ï Á¦17ȸ ¼¼ºê¶õ½º ¾î¸°À̺´¿ø ¼Ò¾Æû¼Ò³âÁúȯ ½ÉÆ÷Áö¾ö : 2024-07-07 0 10 2024-06-19
21101 ¼­¿ï Á¦13ȸ ÁßÀå³â ¿©¼º°Ç°­ ¿¬¼ö°­Á : 2024-06-30 0 4 2024-06-18
21100 ¼­¿ï ´ëÇÑ°¡Àӷº¸Á¸ÇÐȸ Á¦21Â÷ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-06-30 0 7 2024-06-18
21099 ¼­¿ï Á¦ 3ȸ ´ëÇѼҾÆû¼Ò³âÇൿ¹ß´ÞÁõÁø Çмú´ëȸ : 2024-06-30 0 16 2024-06-18
21098 ¼­¿ï 2024 ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-07 0 13 2024-06-19
21097 ´ëÀü Á¦ 19Â÷ ´ëÀüÃæûÁöȸ Åõ¼®½ÉÆ÷Áö¾ö : 2024-07-07 0 13 2024-06-19
21096 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú Á¦22ȸ ¿À°ø ½ÉÆ÷Áö¾ö : 2024-07-07 0 5 2024-06-19
21095 ºÎ»ê Á¦ 9Â÷ ´ëÇÑ»êºÎÀΰúÃÊÀ½ÆÄÇÐȸ ºÎ»ê°æ³²Áöȸ ¿¬¼ö°­Á : 2024-07-07 0 14 2024-06-19
21094 ¼­¿ï Á¦ 2ȸ ´ëÇѼҾƽŰæ¹ß´ÞÇൿ¿¬±¸È¸ Çмú½ÉÆ÷Áö¾ö : 2024-07-07 0 8 2024-06-19
21093 ºÎ»ê (ÇÏÀ̺긮µå) ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ºÎ»ê,¿ï»ê,°æ³²Áöȸ - Á¦2ȸ ¿¬¼ö°­Á : 2024-07-07 0 12 2024-06-19
21092 ¼­¿ï ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ 2024³â ÆÀÇÇÁö¼Ç ½Ç½À °úÁ¤ Part¥° : 2024-07-07 0 4 2024-06-19
21091 ±¤ÁÖ 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ±¤ÁÖÀü³²Áöȸ ¿¬¼ö°­Á : 2024-07-07 0 8 2024-06-19
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷